_:n1c7a6a8be39147a9ae3ca80d9e35c9d2xb0
<http://schema.org/description>
"Primary and secondary objectives were met with 85% or greater relative reduction achieved in the number of new gadolinium-enhancing T1 and new or enlarging T2 hyperintense lesionsNo new safety signals identified  Sanofi’s BTK inhibitor will potentially be first disease-modifying therapy to address sources of multiple sclerosis (MS) damage in the brainSanofi to initiate four Phase 3 clinical trials in relapsing and progressive forms of MSPARIS – April 23, 2020 – Sanofi’s investigational BTK (Bruton's tyrosine kinase) inhibitor, an oral, brain-penetrant, selective small molecule achieved both the primary and secondary endpoints in a Phase 2b trial evaluating efficacy and safety in participants with relapsing forms of multiple sclerosis. The BTK inhibitor (SAR442168) significantly reduced..."
<https://www.pharmiweb.com/press-release/2020-04-24/sanofi-brain-penetrant-btk-inhibitor-significantly-reduced-disease-activity-in-phase-2-trial-in-relapsing-multiple-sclerosis>